Published in Chem Biol on June 01, 2007
Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci (2011) 3.80
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One (2010) 1.87
Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol (2010) 1.69
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol (2009) 1.51
Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol (2011) 1.31
Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. FASEB J (2011) 1.18
Fundamental reaction mechanism and free energy profile for (-)-cocaine hydrolysis catalyzed by cocaine esterase. J Am Chem Soc (2009) 1.15
Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol (2013) 1.14
Distinct roles for CARMIL isoforms in cell migration. Mol Biol Cell (2009) 1.06
Novel human mPGES-1 inhibitors identified through structure-based virtual screening. Bioorg Med Chem (2011) 1.05
Withaferin a alters intermediate filament organization, cell shape and behavior. PLoS One (2012) 1.05
Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. J Biol Chem (2010) 1.03
Role of the cytoskeleton in formation and maintenance of angiogenic sprouts. J Vasc Res (2011) 1.01
A central role for vimentin in regulating repair function during healing of the lens epithelium. Mol Biol Cell (2014) 1.01
Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci (2015) 1.00
Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol Carcinog (2013) 1.00
PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet (2013) 1.00
Anaplasma phagocytophilum AptA modulates Erk1/2 signalling. Cell Microbiol (2010) 0.98
A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS One (2012) 0.98
Natural product inhibitors of ocular angiogenesis. Exp Eye Res (2014) 0.97
Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol (2014) 0.94
The intermediate filament protein, vimentin, is a regulator of NOD2 activity. Gut (2012) 0.91
Calpain-mediated vimentin cleavage occurs upstream of MT1-MMP membrane translocation to facilitate endothelial sprout initiation. Angiogenesis (2012) 0.91
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling. Am J Pathol (2010) 0.89
Computational characterization of how the VX nerve agent binds human serum paraoxonase 1. J Mol Model (2010) 0.87
Vimentin is involved in peptidylarginine deiminase 2-induced apoptosis of activated Jurkat cells. Mol Cells (2014) 0.86
Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One (2012) 0.86
Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin. J Biol Chem (2011) 0.86
A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye. Mol Vis (2011) 0.86
Withaferin A Analogs That Target the AAA+ Chaperone p97. ACS Chem Biol (2015) 0.85
Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. PLoS One (2013) 0.85
Vimentin and PSF act in concert to regulate IbeA+ E. coli K1 induced activation and nuclear translocation of NF-κB in human brain endothelial cells. PLoS One (2012) 0.85
Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer (2010) 0.85
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol (2017) 0.85
Dynamic self-guiding analysis of Alzheimer's disease. Oncotarget (2015) 0.84
Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins. Exp Ther Med (2015) 0.83
Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells. PLoS One (2015) 0.83
Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo. PLoS One (2012) 0.82
Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments. Biochemistry (2011) 0.82
Evidence for partial epithelial-to-mesenchymal transition (pEMT) and recruitment of motile blastoderm edge cells during avian epiboly. Dev Dyn (2011) 0.81
The bat flower: a source of microtubule-destabilizing and -stabilizing compounds with synergistic antiproliferative actions. J Nat Prod (2013) 0.81
Elucidating Molecular Interactions of Natural Inhibitors with HPV-16 E6 Oncoprotein through Docking Analysis. Genomics Inform (2014) 0.81
Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. PLoS One (2013) 0.81
Vimentin, colon cancer progression and resistance to butyrate and other HDACis. J Cell Mol Med (2016) 0.81
Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies. Sci Rep (2015) 0.80
Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling. Exp Cell Res (2014) 0.80
Vimentin Phosphorylation Underlies Myofibroblast Sensitivity to Withaferin A In Vitro and during Corneal Fibrosis. PLoS One (2015) 0.80
Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments. PLoS One (2013) 0.80
Neuromuscular synapse integrity requires linkage of acetylcholine receptors to postsynaptic intermediate filament networks via rapsyn-plectin 1f complexes. Mol Biol Cell (2014) 0.80
Withania somnifera: From prevention to treatment of cancer. Mol Nutr Food Res (2016) 0.80
Human iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arrays. Acta Biomater (2016) 0.79
Covalent modification of the NF-κB essential modulator (NEMO) by a chemical compound can regulate its ubiquitin binding properties in vitro. J Biol Chem (2014) 0.77
Protective effect of Withaferin-A on micronucleus frequency and detoxication agents during experimental oral carcinogenesis. Afr J Tradit Complement Altern Med (2008) 0.77
Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis. Oncol Lett (2017) 0.76
Withaferin a induces proteasome-dependent degradation of breast cancer susceptibility gene 1 and heat shock factor 1 proteins in breast cancer cells. ISRN Biochem (2012) 0.76
Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Sci Rep (2016) 0.76
Withaferin A activates stress signalling proteins in high risk acute lymphoblastic leukemia. Int J Clin Exp Pathol (2015) 0.76
Tumor necrosis factor-α sensitizes breast cancer cells to natural products with proteasome-inhibitory activity leading to apoptosis. PLoS One (2014) 0.76
The Daniel K. Inouye College of Pharmacy Scripts: Poha Berry (Physalis peruviana) with Potential Anti-inflammatory and Cancer Prevention Activities. Hawaii J Med Public Health (2016) 0.75
Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. Org Biomol Chem (2015) 0.75
In Silico Docking to Explicate Interface between Plant-Originated Inhibitors and E6 Oncogenic Protein of Highly Threatening Human Papillomavirus 18. Genomics Inform (2015) 0.75
Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms. Free Radic Biol Med (2016) 0.75
Methods for Determining the Cellular Functions of Vimentin Intermediate Filaments. Methods Enzymol (2015) 0.75
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs (2015) 0.75
Citrullination of glial intermediate filaments is an early response in retinal injury. Mol Vis (2016) 0.75
Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci (2016) 0.75
Pharmacologic inhibition of reactive gliosis blocks TNF-α-mediated neuronal apoptosis. Cell Death Dis (2016) 0.75
Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens. Invest New Drugs (2011) 0.75
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev (2000) 4.11
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A (1997) 3.23
Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell (1994) 3.01
Vimentin is secreted by activated macrophages. Nat Cell Biol (2003) 2.63
Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol (1997) 2.38
Identification of a distinct soluble subunit of an intermediate filament protein: tetrameric vimentin from living cells. Proc Natl Acad Sci U S A (1985) 2.07
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". Mol Pharmacol (2006) 1.95
Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg Med Chem (1998) 1.94
Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci (2000) 1.92
Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis (2004) 1.92
A chemical and genetic approach to the mode of action of fumagillin. Chem Biol (2006) 1.91
Plakins: a family of versatile cytolinker proteins. Trends Cell Biol (2002) 1.91
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Conserved segments 1A and 2B of the intermediate filament dimer: their atomic structures and role in filament assembly. EMBO J (2002) 1.73
Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J (2005) 1.68
Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol (2005) 1.55
Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am J Pharmacogenomics (2004) 1.45
The biology of desmin filaments: how do mutations affect their structure, assembly, and organisation? J Struct Biol (2004) 1.42
Chemical genetics: exploring and controlling cellular processes with chemical probes. Trends Biochem Sci (1999) 1.41
The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem (2005) 1.34
Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res (2003) 1.32
Reduction of renal mass is lethal in mice lacking vimentin. Role of endothelin-nitric oxide imbalance. J Clin Invest (1997) 1.26
Virtual screening on natural products for discovering active compounds and target information. Curr Med Chem (2003) 1.25
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci (2003) 1.22
Endothelial signalling events during leukocyte transmigration. FEBS J (2006) 1.20
Tetracycline regulated expression of vimentin in fibroblasts derived from vimentin null mice. J Cell Sci (1997) 1.14
Under stress, the absence of intermediate filaments from Müller cells in the retina has structural and functional consequences. J Cell Sci (2004) 1.12
A direct interaction between actin and vimentin filaments mediated by the tail domain of vimentin. J Biol Chem (2006) 1.12
How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B (2006) 1.02
Antitumor activity of withaferin A (NSC-101088). Cancer Chemother Rep (1967) 1.01
Characterization of disulfide crosslink formation of human vimentin at the dimer, tetramer, and intermediate filament levels. J Struct Biol (1997) 0.97
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett (1999) 0.96
Vimentin and desmin of a cartilaginous fish, the shark Scyliorhinus stellaris: sequence, expression patterns and in vitro assembly. Eur J Cell Biol (2001) 0.95
Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett (2006) 0.95
Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Invest Ophthalmol Vis Sci (2006) 0.95
Intermediate filaments: vimentin moves in. Curr Biol (2002) 0.93
Novel cytotoxic and antitumor agents. IV. Withaferin A: relation of its structure to the in vitro cytotoxic effects on P388 cells. Neoplasma (1984) 0.91
Forced expression of desmin and desmin mutants in cultured cells: impact of myopathic missense mutations in the central coiled-coil domain on network formation. Exp Cell Res (2006) 0.90
Dynamics of the expression of cytoskeleton components and adherens molecules by fibroblastic cells in alkali-burned and lacerated corneas. Exp Eye Res (1994) 0.88
Cytoskeletal rearrangement by oxidative stress. Int J Tissue React (1989) 0.82
In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development. J Pharm Pharmacol (2006) 0.79
Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A (2005) 2.63
Vimentin is secreted by activated macrophages. Nat Cell Biol (2003) 2.63
Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc (2008) 2.33
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol (2008) 1.79
Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J Phys Chem B (2005) 1.73
Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol (2010) 1.69
Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J Am Chem Soc (2007) 1.63
Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res (2009) 1.61
Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol (2008) 1.60
Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew Chem Int Ed Engl (2006) 1.55
Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol (2010) 1.48
Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J Am Chem Soc (2008) 1.45
Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases. J Phys Chem B (2005) 1.44
PotD protein stimulates biofilm formation by Escherichia coli. Biotechnol Lett (2013) 1.44
Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins (2006) 1.43
Detection of HERV-K(HML-2) viral RNA in plasma of HIV type 1-infected individuals. AIDS Res Hum Retroviruses (2006) 1.40
Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact (2010) 1.39
The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology (2003) 1.36
LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol (2007) 1.35
First-principles calculation of pKa for cocaine, nicotine, neurotransmitters, and anilines in aqueous solution. J Phys Chem B (2007) 1.34
Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. Nat Chem Biol (2011) 1.31
The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol (2006) 1.27
How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys J (2007) 1.27
Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals. J Virol (2011) 1.26
Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys J (2009) 1.25
p300/CBP-associated factor drives DEK into interchromatin granule clusters. J Biol Chem (2005) 1.24
The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol (2004) 1.22
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther (2009) 1.19
Theoretical studies of the transition-state structures and free energy barriers for base-catalyzed hydrolysis of amides. J Phys Chem A (2006) 1.19
Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses (2008) 1.18
Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the gammaTuRC to the centrosome. J Cell Sci (2009) 1.17
The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev (2011) 1.17
PCM1 recruits Plk1 to the pericentriolar matrix to promote primary cilia disassembly before mitotic entry. J Cell Sci (2013) 1.15
Reaction pathways and free energy barriers for alkaline hydrolysis of insecticide 2-trimethylammonioethyl methylphosphonofluoridate and related organophosphorus compounds: electrostatic and steric effects. J Org Chem (2004) 1.15
Fundamental reaction mechanism and free energy profile for (-)-cocaine hydrolysis catalyzed by cocaine esterase. J Am Chem Soc (2009) 1.15
Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma. J Virol (2002) 1.14
Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol (2013) 1.14
Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J Phys Chem B (2009) 1.13
A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol Pharmacol (2010) 1.12
A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem (2010) 1.12
Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention. Mol Pharmacol (2008) 1.12
Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose? Future Med Chem (2012) 1.10
Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1. J Virol (2012) 1.10
Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel (2010) 1.10
Coordination number of zinc ions in the phosphotriesterase active site by molecular dynamics and quantum mechanics. J Comput Chem (2003) 1.09
Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency. Biochemistry (2010) 1.09
Computational simulations of the interactions between acetyl-coenzyme-A carboxylase and clodinafop: resistance mechanism due to active and nonactive site mutations. J Chem Inf Model (2009) 1.08
NGSQC: cross-platform quality analysis pipeline for deep sequencing data. BMC Genomics (2010) 1.07
A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proc Natl Acad Sci U S A (2009) 1.06
Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One (2013) 1.06
DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum (2011) 1.06
Novel human mPGES-1 inhibitors identified through structure-based virtual screening. Bioorg Med Chem (2011) 1.05
Modeling multiple species of nicotine and deschloroepibatidine interacting with alpha4beta2 nicotinic acetylcholine receptor: from microscopic binding to phenomenological binding affinity. J Am Chem Soc (2005) 1.05
An efficient implementation for determining volume polarization in self-consistent reaction field theory. J Chem Phys (2008) 1.05
Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. PLoS Comput Biol (2012) 1.04
Hydrophilic anilinogeranyl diphosphate prenyl analogues are Ras function inhibitors. Biochemistry (2006) 1.03
HIV infection reveals widespread expansion of novel centromeric human endogenous retroviruses. Genome Res (2013) 1.03
Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. J Biol Chem (2010) 1.03
How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B (2006) 1.02
YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene (2002) 1.02
AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers. Int J Gynecol Cancer (2011) 1.00
Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. J Am Chem Soc (2011) 1.00
Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction. Org Biomol Chem (2007) 1.00
Leukocytic promotion of prostate cellular proliferation. Prostate (2010) 0.98
Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol (2010) 0.98
Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. J Med Chem (2006) 0.98
DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Stem Cells Dev (2011) 0.98
Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects. J Biol Chem (2002) 0.97
Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1. J Chem Inf Model (2008) 0.97
Preparation and in vivo characterization of a cocaine hydrolase engineered from human butyrylcholinesterase for metabolizing cocaine. Biochem J (2013) 0.96
Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem (2009) 0.96
Effect of dietary fat on early morphological intestinal adaptation in a rat with short bowel syndrome. Pediatr Surg Int (2004) 0.96
Reaction pathway and free-energy barrier for reactivation of dimethylphosphoryl-inhibited human acetylcholinesterase. J Phys Chem B (2009) 0.95
Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations. J Phys Chem B (2010) 0.95
Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett (2006) 0.95
Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Invest Ophthalmol Vis Sci (2006) 0.95
Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther (2009) 0.94
DEK binding to class II MHC Y-box sequences is gene- and allele-specific. Arthritis Res Ther (2003) 0.94
Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains. AIDS Res Hum Retroviruses (2012) 0.93
QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorg Med Chem (2006) 0.93
Minireview: DEK and gene regulation, oncogenesis and AIDS. Anticancer Res (2003) 0.93